This inventor holds 2 USPTO granted patents. Top assignee: The University of North Carolina at Chapel Hill. Active years: 2007-2009.
Location History:
- Chapel Hill, NC (US) (2007)
- Frederick, MD (US) (2009)
Company Filing History:
Years Active: 2007-2009
Title: Innovations of Kristopher M Curtis
Introduction
Kristopher M Curtis is an accomplished inventor based in Frederick, MD (US). He has made significant contributions to the field of virology, particularly in the development of compositions related to coronaviruses. With a total of 2 patents, his work has implications for vaccine development and infectious disease research.
Latest Patents
Curtis's latest patents include groundbreaking inventions such as "Compositions of coronaviruses with a recombination-resistant genome." This invention provides a cDNA of a severe acute respiratory syndrome (SARS) coronavirus, recombinant SARS coronavirus vectors, and SARS coronavirus replicon particles. The patent also outlines methods for making these compositions and their use as immunogens, vaccines, or to express heterologous nucleic acids. Another notable patent is "Methods for producing recombinant coronavirus," which describes a helper cell for producing infectious, replication-defective nidovirus particles. This invention details the combined expression of replicon RNA and helper RNA in a nidovirus permissive cell, resulting in an assembled nidovirus particle capable of infecting a cell.
Career Highlights
Curtis is affiliated with the University of North Carolina at Chapel Hill, where he continues to advance research in his field. His innovative work has positioned him as a key figure in the study of coronaviruses and their potential treatments.
Collaborations
He has collaborated with notable researchers such as Ralph Baric and Boyd Yount, further enhancing the impact of his work in the scientific community.
Conclusion
Kristopher M Curtis's contributions to virology through his patents and research collaborations highlight his role as an influential inventor in the field. His work continues to pave the way for advancements in vaccine development and infectious disease management.
